COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device (COOLEY)
Acute-On-Chronic Liver Failure, Anticoagulant Adverse Reaction, Sarcopenia
About this trial
This is an interventional treatment trial for Acute-On-Chronic Liver Failure focused on measuring acute on chronic liver failure, sarcopenia, citrate anticoagulation, low molecular weight heparins, hand grip strength, skeletal muscle ultrasound, hemoadsorption, CRRT
Eligibility Criteria
Inclusion Criteria: adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium. Written informed consent from patient or if not possible due to encephalopathy (> grade 2): legal representative acute-on-chronic liver failure (ACLF) grade ≥ 2: Acute decompensation event (identifiable trigger) Hepatic encephalopathy grade ≥ 2 Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours) Serum bilirubin ≥ 10 mg/dl Hemodynamic instability with vasopressor support (norepinephrine > 0.05 mcg/kg/min) Exclusion Criteria: • known patient will against participation in the study or against the measures applied in the study a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours no complete remission of malignancy including hepatocellular carcinoma within the past 12 months ongoing intermittent or CRRT before study inclusion
Sites / Locations
- UZA
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
CytoSorb hemoadsorption
Control group
Patients with acute on chronic liver failure will receive CytoSorb treatment for 72 hours. The aim is to remove the molecules that drive systemic inflammation.
Historical group that received only standard medical care